Agenus Inc AGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
-
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
-
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
-
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
-
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
-
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
-
Agenus to Participate in Upcoming September Investor Conferences
-
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 45.16M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.77
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 81
- Website
- https://www.agenusbio.com
Valuation
|
Metric
|
AGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.77 |
Price/Cash Flow | — |
Price/Earnings
AGEN
Financial Strength
|
Metric
|
AGEN
|
|---|---|
Quick Ratio | 0.18 |
Current Ratio | 0.34 |
Interest Coverage | 2.56 |
Quick Ratio
AGEN
Profitability
|
Metric
|
AGEN
|
|---|---|
Return on Assets (Normalized) | −11.83% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
AGEN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?L>k&<# | LOCK|Jdm<H | $133B | |||
| Moderna Inc
MRNA
| LOCK|@&sZ<B | LOCK|@@% | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|l$&@R# | LOCK|Ln$c | $83B | |||
| argenx SE ADR
ARGX
| LOCK|^^<j?# | LOCK|W%^ | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>&jm%g | LOCK|YS | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|nx>R#% | LOCK|RnDh | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H>@&Nkhj | LOCK|GL%^ | $28B | |||
| Incyte Corp
INCY
| LOCK|!yl%zr | LOCK|<g$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|np?w@j> | LOCK|$X# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^#jj>?& | LOCK|H>& | $14B |
United States